Clinical Trial Update: A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating safety, efficacy, pharmacokinetics, and immunogenicity of Test Pertuzumab (ZRC-3277) by Cadila Healthcare Ltd. has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Test Pertuzumab (ZRC-3277) (pertuzumab)

Snippet

Sponsor: Zydus Lifesciences Limited | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED